Trial Profile
TRIUMPH I: Double Blind Placebo Controlled Clinical Investigation Into the Efficacy and Tolerability of Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Jan 2024
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Acronyms TRIUMPH I
- Sponsors United Therapeutics Corporation
- 13 Sep 2023 Primary endpoint (Peak 6-minute Walk Distance) has been met according to results presented at the 33rd Annual Congress of the European Respiratory Society.
- 13 Sep 2023 Results of post hoc analysis assessing To explore the effects of inhaled treprostinil (iTre) on PAH patients with 1 cardiovascular comorbidity in the pivotal TRIUMPH study presented at the 33rd Annual Congress of the European Respiratory Society
- 25 Jun 2014 New trial record